ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

ClinicalTrials.gov ID: NCT04908475

Public ClinicalTrials.gov record NCT04908475. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 12:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Study identification

NCT ID
NCT04908475
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
AbbVie
Industry
Enrollment
352 participants

Conditions and interventions

Conditions

Interventions

  • Apremilast Drug
  • Risankizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 8, 2021
Primary completion
Apr 19, 2023
Completion
Apr 19, 2023
Last update posted
Apr 29, 2024

2021 – 2023

United States locations

U.S. sites
26
U.S. states
16
U.S. cities
25
Facility City State ZIP Site status
Total Skin and Beauty Dermatology Center /ID# 233793 Birmingham Alabama 35205
Advanced Research Associates - Glendale /ID# 229266 Glendale Arizona 85308
Alliance Dermatology and MOHs Center, PC /ID# 229224 Phoenix Arizona 85032
UC Davis Health /ID# 229133 Sacramento California 95816-3300
Florida Academic Centers Research and Education /ID# 229235 Coral Gables Florida 33134
Olympian Clinical Research - Largo /ID# 233792 Largo Florida 33770
Renstar Medical Research /ID# 228946 Ocala Florida 34470
ForCare Clinical Research /ID# 229135 Tampa Florida 33613-1244
Arlington Dermatology /ID# 228945 Rolling Meadows Illinois 60008
Dawes Fretzin, LLC /ID# 229010 Indianapolis Indiana 46256
Epiphany Dermatology of Kansas LLC /ID# 229221 Overland Park Kansas 66210
DermAssociates, LLC /ID# 229016 Rockville Maryland 20850
Michigan Center for Research Company /ID# 229136 Clarkston Michigan 48346
Henry Ford Medical Center /ID# 229215 Detroit Michigan 48202-3046
MediSearch Clinical Trials /ID# 229269 Saint Joseph Missouri 64506
Physician Research Collaboration, LLC /ID# 229225 Lincoln Nebraska 68516
Advanced Dermatology of the Midlands /ID# 229009 Omaha Nebraska 68144-1105
Psoriasis Treatment Center of Central New Jersey /ID# 228943 East Windsor New Jersey 08520
University Hospitals Case Medical Center /ID# 229240 Cleveland Ohio 44106
Wright State Physicians - Fairborn /ID# 230051 Fairborn Ohio 45324-2640
Oregon Dermatology and Research Center /ID# 233462 Portland Oregon 97210
Arlington Research Center, Inc /ID# 229264 Arlington Texas 76011
Bellaire Dermatology Associates /ID# 230118 Bellaire Texas 77401
Center for Clinical Studies - Houston (Binz) /ID# 229263 Houston Texas 77004-8097
Center for Clinical Studies - Houston (Binz) /ID# 229272 Houston Texas 77004-8097
Premier Clinical Research /ID# 229220 Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04908475, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 29, 2024 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04908475 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →